Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease

THU0097 Systematic review of the safety of protein kinase inhibitors in clinical trials in rheumatoid arthritis:

(2014) E. Salgado et al.   ANNALS OF THE RHEUMATIC DISEASES

Cardiovascular Comorbidity in COPD

(2013) Hana Müllerova et al.   CHEST

C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate With Coronary Atheroma Regression and Cardiovascular Events After Maximally Intensive Statin Therapy

(2013) Rishi Puri et al.   CIRCULATION

A meta-analysis of the role of p38 mitogen-activated protein kinase inhibitors in patients with active rheumatoid arthritis

(2013) Lan Li et al.   CLINICAL RHEUMATOLOGY

Losmapimod concentration–QT relationship in healthy volunteers: meta-analysis of data from six clinical trials

(2013) Shuying Yang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

p38 MAPK Inhibitor, CBS3830 Limits Vascular Remodelling in Arterialised Vein Grafts

(2013) Jian-Jun Ge et al.   Heart Lung and Circulation

Immune Effector Mechanisms Implicated in Atherosclerosis: From Mice to Humans

(2013) Peter Libby et al.   IMMUNITY

Monocyte heterogeneity in cardiovascular disease

(2013) Peter Libby et al.   Seminars in Immunopathology

Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial

(2013) William MacNee et al.   THORAX

The Study Of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): Design and rationale

(2012) Chiara Melloni et al.   AMERICAN HEART JOURNAL

Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers

(2012) April M. Barbour et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Vascular Risk in Chronic Obstructive Pulmonary Disease: Role of Inflammation and Other Mediators

(2012) S.F. Paul Man et al.   CANADIAN JOURNAL OF CARDIOLOGY

New Therapeutic Targets in Cardiology

(2012) Eva Denise Martin et al.   CIRCULATION

Anti-Tumor Necrosis Factor-α Therapy Reduces Aortic Inflammation and Stiffness in Patients With Rheumatoid Arthritis

(2012) Kaisa M. Mäki-Petäjä et al.   CIRCULATION

Population Pharmacokinetics of Losmapimod in Healthy Subjects and Patients with Rheumatoid Arthritis and Chronic Obstructive Pulmonary Diseases

(2012) Shuying Yang et al.   CLINICAL PHARMACOKINETICS

Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study

(2012) T. Ostenfeld et al.   EUROPEAN JOURNAL OF PAIN

Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs

(2012) Kate Gaffey et al.   EUROPEAN RESPIRATORY JOURNAL

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Stephen S Lim et al.   LANCET

Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome

(2012) L Sokol et al.   LEUKEMIA

C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of p38 Mitogen-Activated Protein Kinase Inhibition on Vascular and Systemic Inflammation in Patients With Atherosclerosis

(2012) Maysoon Elkhawad et al.   JACC-Cardiovascular Imaging

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

(2011) Paul M Ridker et al.   AMERICAN HEART JOURNAL

Inhibition of p38 Mitogen-Activated Protein Kinase Improves Nitric Oxide–Mediated Vasodilatation and Reduces Inflammation in Hypercholesterolemia

(2011) Joseph Cheriyan et al.   CIRCULATION

Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury

(2011) Praveen Anand et al.   EUROPEAN JOURNAL OF PAIN

Effects of Statins on Serum Inflammatory Markers: The U.S. National Health and Nutrition Examination Survey 1999-2004

(2011) Sung Sug (Sarah) Yoon et al.   Journal of Atherosclerosis and Thrombosis

Novel p38α Mitogen-Activated Protein Kinase Inhibitor Shows Analgesic Efficacy in Acute Postsurgical Dental Pain

(2011) Sandra E. Tong et al.   JOURNAL OF CLINICAL PHARMACOLOGY

An Oral Inhibitor of p38 MAP Kinase Reduces Plasma Fibrinogen in Patients With Chronic Obstructive Pulmonary Disease

(2011) David A. Lomas et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis

(2011) MARK C. GENOVESE et al.   JOURNAL OF RHEUMATOLOGY

Distinct regulation of B-type natriuretic peptide transcription by p38 MAPK isoforms

(2011) Elina Koivisto et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Tumor necrosis factor superfamily molecules in acute coronary syndromes

(2010) Pål Aukrust et al.   ANNALS OF MEDICINE

Inhibition of p38 Mitogen-Activated Protein Kinase Reduces Inflammation After Coronary Vascular Injury in Humans

(2010) Lea Sarov-Blat et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The Role of Heat Shock Protein (HSP) in Atherosclerosis: Pathophysiology and Clinical Opportunities

(2010) X. Lu et al.   CURRENT MEDICINAL CHEMISTRY

The p38 mitogen-activated protein kinase pathway—A potential target for intervention in infarction, hypertrophy, and heart failure

(2010) Michael S. Marber et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Increased Glucose Uptake in Visceral Versus Subcutaneous Adipose Tissue Revealed by PET Imaging

(2010) Thomas Christen et al.   JACC-Cardiovascular Imaging

The Cytokine Network in Chronic Obstructive Pulmonary Disease

(2009) Peter J. Barnes   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

"Go upstream, young man": lessons learned from the p38 saga

(2009) D Hammaker et al.   ANNALS OF THE RHEUMATIC DISEASES

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

(2009) Stanley B. Cohen et al.   ARTHRITIS AND RHEUMATISM

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies

(2009) Nemanja Damjanov et al.   ARTHRITIS AND RHEUMATISM

Inhibition of p38: Has the fat lady sung?

(2009) Mark C. Genovese   ARTHRITIS AND RHEUMATISM

Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression

(2009) Florian H. Seeger et al.   BASIC RESEARCH IN CARDIOLOGY

Nox4 overexpression activates reactive oxygen species and p38 MAPK in human endothelial cells

(2009) Claudia Goettsch et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A Chemical Genetic Approach Reveals That p38α MAPK Activation by Diphosphorylation Aggravates Myocardial Infarction and Is Prevented by the Direct Binding of SB203580

(2009) Sarawut Kumphune et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Randomized, Placebo-Controlled Study of the Effects of the p38 MAPK Inhibitor SB-681323 on Blood Biomarkers of Inflammation in COPD Patients

(2009) Dave Singh et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Selective p38α Inhibitors Clinically Evaluated for the Treatment of Chronic Inflammatory Disorders

(2009) David M. Goldstein et al.   JOURNAL OF MEDICINAL CHEMISTRY

Differential Effects of p38 Mitogen-Activated Protein Kinase and Cyclooxygenase 2 Inhibitors in a Model of Cardiovascular Disease

(2009) R. N. Willette et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Requirement for p38 Mitogen-Activated Protein Kinase Activity in Neointima Formation After Vascular Injury

(2008) Brandon M. Proctor et al.   CIRCULATION

Pericardial Fat, Visceral Abdominal Fat, Cardiovascular Disease Risk Factors, and Vascular Calcification in a Community-Based Sample

(2008) Guido A. Rosito et al.   CIRCULATION

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased activation of p38 MAPK in COPD

(2007) T. Renda et al.   EUROPEAN RESPIRATORY JOURNAL